Table 2. Performance of hrHPV-DNA testing, cytology and cotesting according to the follow-up visit of conservatively treated AIS patients.

	hrHPV DNA (%)	Cytology (%)	Cotesting (%)
First FU visit
Sensitivity	90	60	90
Specificity	58	69	50
PPV	64	55	52
NPV	88	73	89
Second FU visit
Sensitivity	84	66	100
Specificity	59	73	52
PPV	42	44	40
NPV	91	87	100

AIS: Adenocarcinoma in situ,

PPV: positive predictive value,

NPV: negative predictive value.